Literature DB >> 10375538

Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.

Y T Chang1, N S Gray, G R Rosania, D P Sutherlin, S Kwon, T C Norman, R Sarohia, M Leost, L Meijer, P G Schultz.   

Abstract

BACKGROUND: Purines constitute a structural class of protein ligands involved in mediating an astonishing array of metabolic processes and signal pathways in all living organisms. Synthesis of purine derivatives targeting specific purine-binding proteins in vivo could lead to versatile lead compounds for use as biological probes or drug candidates.
RESULTS: We synthesized several libraries of 2,6, 9-trisubstituted purines using both solution- and solid-phase chemistry, and screened the compounds for inhibition of cyclin-dependent kinase (CDK) activity and human leukemic cell growth. Lead compounds were optimized by iterative synthesis based on structure-activity relationships (SARs), as well as analysis of several CDK-inhibitor cocrystal structures, to afford several interesting compounds including one of the most potent CDK inhibitors known to date. Unexpectedly, some compounds with similar CDK inhibitory activity arrested cellular proliferation at distinctly different phases of the cell cycle and another inhibitor directly induced apoptosis, bypassing cell-cycle arrest. Some of these compounds selectively inhibited growth of cells derived from specific tumors.
CONCLUSIONS: 2,6,9-Trisubstituted purines have various and potent biological activities, despite high concentrations of competing endogenous purine ligands in living cells. Purine libraries constitute a versatile source of small molecules that affect distinct biochemical pathways mediating different cellular functions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10375538     DOI: 10.1016/S1074-5521(99)80048-9

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  30 in total

Review 1.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.

Authors:  Katrien Vermeulen; Dirk R Van Bockstaele; Zwi N Berneman
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

2.  Surrogate docking: structure-based virtual screening at high throughput speed.

Authors:  Sukjoon Yoon; Andrew Smellie; David Hartsough; Anton Filikov
Journal:  J Comput Aided Mol Des       Date:  2005-11-16       Impact factor: 3.686

Review 3.  A cheminformatic toolkit for mining biomedical knowledge.

Authors:  Gus R Rosania; Gordon Crippen; Peter Woolf; David States; Kerby Shedden
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

4.  c-Myc is necessary for DNA damage-induced apoptosis in the G(2) phase of the cell cycle.

Authors:  S Adachi; A J Obaya; Z Han; N Ramos-Desimone; J H Wyche; J M Sedivy
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

5.  Diverse effects of the cyclin-dependent kinase inhibitor bohemine: Concentration- and time-dependent suppression or stimulation of hybridoma culture.

Authors:  F Franek; M Strnad; L Havlícek; V Siglerová; I Fismolová; T Eckschlager
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

6.  A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.

Authors:  Yihui Shi; Jaehyeon Park; Chandraiah Lagisetti; Wei Zhou; Lidia C Sambucetti; Thomas R Webb
Journal:  Bioorg Med Chem Lett       Date:  2016-12-24       Impact factor: 2.823

7.  VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells.

Authors:  Lymor Ringer; Paul Sirajuddin; Mary Heckler; Anup Ghosh; Frank Suprynowicz; Venkata M Yenugonda; Milton L Brown; Jeffrey A Toretsky; Aykut Uren; YiChien Lee; Tobey J MacDonald; Olga Rodriguez; Robert I Glazer; Richard Schlegel; Chris Albanese
Journal:  Cancer Biol Ther       Date:  2011-11-01       Impact factor: 4.742

8.  Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.

Authors:  Joydev K Laha; Xuemei Zhang; Lixin Qiao; Min Liu; Snigdha Chatterjee; Shaughnessy Robinson; Kenneth S Kosik; Gregory D Cuny
Journal:  Bioorg Med Chem Lett       Date:  2011-02-03       Impact factor: 2.823

Review 9.  New targets and inhibitors of mycobacterial sulfur metabolism.

Authors:  Hanumantharao Paritala; Kate S Carroll
Journal:  Infect Disord Drug Targets       Date:  2013-04

Review 10.  CDK inhibitors in cancer therapy, an overview of recent development.

Authors:  Mengna Zhang; Lingxian Zhang; Ruoxuan Hei; Xiao Li; Haonan Cai; Xuan Wu; Qiping Zheng; Cheguo Cai
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.